Part of the 2026 AUA Innovation Nexus Forum, the showcase will feature 43 global innovators in urology
January 15, 2026 (HAMILTON, ON) — Insight Medbotics is among the 43 global innovators presenting at the American Urology Association’s (AUA) 2026 Innovation Nexus Showcase. The one-day event offers a first look at emerging technologies shaping innovation in urologic care. As part of the association’s annual forum, it will take place on May 14, 2026 in Washington, DC.
This year, AUA has expanded its showcase beyond incubators to add companies at every stage of startup development. Participants gain the opportunity to showcase their solutions, receive expert feedback, and build the connections needed to advance funding, partnerships, and commercialization.
Insight Medbotics is seeking Series A investment to advance precision cancer care in urology. Glenn™, its next-generation robotics platform, is designed to expand access to MRI-guided precision for urologists. Glenn leverages the company’s previous work on MRI-compatible and clinically demonstrated robotics in breast biopsy; the IGAR robotics system is the only robotics system designed for use with MRI scanners to receive 510(k) clearance from the FDA.
Glenn digitizes the entire care pathway, offering data-driven clinical insight in ways that haven’t been possible before, giving urologists intuitive MRI access while removing the guesswork of traditional ultrasound guidance methods.
“AUA is a leading organizational advocate for best practice in urology. Being selected to present through their competitive application process underscores the importance of improved MRI access for urologists in both hospital and private practice settings,” says Fazila Seker, CEO and Board Director of Insight Medbotics.
“Last year, we demonstrated Glenn’s capabilities to 49 American urologists, who taught us more about the importance of removing the guesswork from prostate cancer care and our solution, designed to help close that gap. This year, we're extending our relationships with physicians who expressed interest in using Glenn in their practices while advancing prostate cancer care for their patients. With over 24,000 worldwide members, being invited to share AUA’s stage further validates our market approach while giving us the opportunity to pitch investors who understand the existing challenges in patient care for this field.”
The selected innovators span every stage of development, from pre‑seed and idea‑stage companies to post‑Series A ventures, and reflect a diverse range of technologies advancing urologic care.
“The 43 innovators selected for this year’s Innovation Nexus Showcase represent some of the most promising and impactful advances in urology today,” said Innovation Nexus Physician Director, Steven Kaplan, MD, FACS. “Each presenter was carefully chosen for the strength of their science, the clinical relevance of their solution, and their potential to meaningfully improve patient care. Collectively, this group reflects both the depth of innovation in our field and the AUA’s commitment to elevating ideas that are ready to shape the future of urologic health.”
Registration for the 2026 AUA Innovation Nexus Forum is open. To learn more, visit www.auanexus.org/events/forum/registration.
